OncoSTING Overview
- Founded
- 2018
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $150K
- Investors
- 2
OncoSTING General Information
Description
Developer of therapies designed to cure bladder cancer. The company's therapies work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.
Contact Information
Website
www.oncosting.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Primary Office
- Baltimore, MD
- United States
OncoSTING Timeline
OncoSTING Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 02-Jul-2019 | $150K | 00000 | Completed | Startup | |
| 3. Accelerator/Incubator | 28-Jun-2019 | Completed | Startup | |||
| 2. Grant | 01-Jul-2018 | Completed | Startup | |||
| 1. Grant | 23-Feb-2018 | Completed | Startup |
OncoSTING Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ambaw Bellete | President & Business Advisor | ||
| Trinity Bivalacqua Ph.D | Co-Founder | ||
| William Bishai Ph.D | Co-Founder |
OncoSTING Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Johns Hopkins University Endowment | Limited Partner | 000 0000 | 000000 0 | ||
| TEDCO | Venture Capital | Minority | 000 0000 | 000000 0 |